Company announcement no. 8 – 2512 May 2025 NTG Nordic Transport Group publishes interim report for Q1 2025 The interim…
COPENHAGEN, Denmark, May 9, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today its interim financial results and business progress…
Antwerp, Belgium, May 6, 2025 – Agomab Therapeutics NV (“Agomab”) today announced late-breaking interim data from the ongoing STENOVA1 Phase…
April 26, 2025 10:00 ET | Source: Protara Therapeutics TARA-002 demonstrates 100% complete response rate at any time and 67%…
ORION CORPORATION INTERIM REPORT 1–3/2025 23 APRIL 2025 at 12:00 EEST Orion Group Interim Report January–March 2025 January–March 2025 Highlights…
Non-human primate pharmacokinetics data suggests IBIO-600, a potentially best-in-class long-acting anti-myostatin antibody, could have a human half-life as long as…
SAN FRANCISCO and BOSTON, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing…
January 29, 2025 08:00 ET | Source: 4D Molecular Therapeutics, Inc. Initial interim 52-week results from Phase 2b Population Extension…
Company announcement No. 06/2025 28 January 2025 Continued growth and margin improvement in a challenging marketSummary full year 2024…
– ABI-4334 was well-tolerated with a favorable safety profile and half-life supporting once-daily oral dosing observed – – In the…
